Integra LifeSciences Holdings Corp.has been pleasing the market with its 2016 financial performance, 2017 M&A schedule and 2017–18 outlook. At some point, the group aims to reach aspirational targets of $2 billion in sales and 30% EBITDA margin as it establishes itself as a diversified medical technology group.
Its M&A has been making most of the headlines, but as Integra president and CEO Peter Arduini told investors on...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?